Drug Profile
Adalimumab biosimilar - Meridian Biopharmaceuticals
Alternative Names: MB 612Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Meridian Biopharmaceuticals
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Immunological-disorders in Austria (SC, Injection)
- 15 May 2015 Early research in Immunological disorders in Austria (Parenteral)